Webdisclosure.com

Search

ARIX BIOSCIENCE PLC Transaction in own shares

Directive transparence : information réglementée

06/04/2021 18:25

Arix Bioscience PLC (ARIX)
Transaction in own shares

06-Apr-2021 / 17:25 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

 

Transaction in own shares

 

LONDON, 06 April 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

 

Date of purchase

06 April 2021

Aggregate number of shares purchased

87,000

Highest price paid per share

190.00p

Lowest price paid per share

186.25p

Average price paid per share

189.31p

 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 134,809,653 ordinary shares of 0.001 pence each in issue (excluding 800,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.             

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

06/04/2021

09:03:40

5,347

186.25

London Stock Exchange

00233283323TRLO0

06/04/2021

10:29:17

2,175

188.50

London Stock Exchange

00233329847TRLO0

06/04/2021

11:32:12

50,000

190.00

London Stock Exchange

00233361113TRLO0

06/04/2021

13:30:41

15,000

189.00

London Stock Exchange

00233414100TRLO0

06/04/2021

16:19:00

14,478

188.50

London Stock Exchange

00233557356TRLO0

 

 

 

ISIN: GB00BD045071

Category Code: MSCH

TIDM: ARIX

LEI Code: HQCXNIX43

 



ISIN: GB00BD045071
Category Code: POS
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares
Sequence No.: 97384
EQS News ID: 1181509

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1181509&application_name=news&site_id=symex

20/04/2021 18:30
19/04/2021 18:09
16/04/2021 18:17
15/04/2021 18:08
14/04/2021 18:13
13/04/2021 18:13
12/04/2021 18:22
09/04/2021 18:43
08/04/2021 18:27
08/04/2021 08:00